Bristol-Myers Squibb

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. 

CEO
Christopher S. Boerner
CEOChristopher S. Boerner
Employees
32,500
Employees32,500
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
1933
Founded1933
Employees
32,500
Employees32,500

BMY Key Statistics

Market cap
118.97B
Market cap118.97B
Price-Earnings ratio
16.70
Price-Earnings ratio16.70
Dividend yield
4.31%
Dividend yield4.31%
Average volume
8.29M
Average volume8.29M
High today
$58.71
High today$58.71
Low today
$57.91
Low today$57.91
Open price
$58.59
Open price$58.59
Volume
6.27M
Volume6.27M
52 Week high
$62.89
52 Week high$62.89
52 Week low
$42.52
52 Week low$42.52

Stock Snapshot

With a market cap of 118.97B, Bristol-Myers Squibb(BMY) trades at $58.30. The stock has a price-to-earnings ratio of 16.70 and currently yields dividends of 4.3%.

As of 2026-04-29, Bristol-Myers Squibb(BMY) stock has fluctuated between $57.91 and $58.71. The current price stands at $58.30, placing the stock +0.7% above today's low and -0.7% off the high.

The Bristol-Myers Squibb(BMY)'s current trading volume is 6.27M, compared to an average daily volume of 8.29M.

During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $62.89 at its peak.

During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $62.89 at its peak.

BMY News

Simply Wall St 1h
Does Expanded MTAP-CDx Partnership With Foundation Medicine Change The Bull Case For Bristol-Myers Squibb?

Earlier this month, Foundation Medicine announced an expanded collaboration with Bristol-Myers Squibb to develop FoundationOne CDx as a next-generation sequenci...

Does Expanded MTAP-CDx Partnership With Foundation Medicine Change The Bull Case For Bristol-Myers Squibb?
Simply Wall St 6d
Bristol Myers Squibb Aligns MTAP Precision Oncology Push With Solar Shift

Bristol Myers Squibb (NYSE:BMY) has expanded its collaboration with Foundation Medicine to develop a next generation sequencing companion diagnostic to identify...

Bristol Myers Squibb Aligns MTAP Precision Oncology Push With Solar Shift

Analyst ratings

59%

of 32 ratings
Buy
37.5%
Hold
59.4%
Sell
3.1%

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.